According to STAT News data, U.S. healthcare spending increased 7.3% in 2025, reaching approximately $6 trillion—a sharp acceleration compared to prior years’ growth rates of 3.9% (2023) and 4.8% (2024). This surge represents the steepest annual increase in recent healthcare history, signaling structural changes in pharmaceutical utilization patterns across the nation.
GLP-1 receptor agonists, including semaglutide and tirzepatide, have emerged as significant cost contributors to this spending explosion. These medications, which can cost over $1,000 monthly without insurance coverage, are now prescribed across millions of patients for both approved diabetes indications and off-label weight management applications. The combination of high per-unit costs and rapidly expanding patient populations has created substantial financial pressure on insurers, healthcare systems, and patients navigating affordability challenges.
Read the full article on GMJ Newsroom.
Was this article helpful?
